[go: up one dir, main page]

ID20600A - Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit - Google Patents

Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit

Info

Publication number
ID20600A
ID20600A IDP981018A ID981018A ID20600A ID 20600 A ID20600 A ID 20600A ID P981018 A IDP981018 A ID P981018A ID 981018 A ID981018 A ID 981018A ID 20600 A ID20600 A ID 20600A
Authority
ID
Indonesia
Prior art keywords
profilactic
modified cells
disease therapy
genetic modified
genetic
Prior art date
Application number
IDP981018A
Other languages
English (en)
Indonesian (id)
Inventor
Klaus Havemann
Rolf Muller
Hans Harald Sedlacek
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19731154A external-priority patent/DE19731154C2/de
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of ID20600A publication Critical patent/ID20600A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDP981018A 1997-07-21 1998-07-17 Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit ID20600A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19731154A DE19731154C2 (de) 1997-07-21 1997-07-21 Genetisch veränderte Endothelzellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
DE19752299 1997-11-26

Publications (1)

Publication Number Publication Date
ID20600A true ID20600A (id) 1999-01-21

Family

ID=26038441

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP981018A ID20600A (id) 1997-07-21 1998-07-17 Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit

Country Status (14)

Country Link
US (1) US20020098166A1 (es)
EP (1) EP0893493A3 (es)
JP (1) JPH1189587A (es)
KR (1) KR19990014018A (es)
AR (1) AR015926A1 (es)
AU (1) AU757960B2 (es)
BR (1) BR9802542A (es)
CA (1) CA2237698A1 (es)
CZ (1) CZ227198A3 (es)
HU (1) HUP9801634A3 (es)
ID (1) ID20600A (es)
PL (1) PL327624A1 (es)
RU (1) RU2205029C2 (es)
TR (1) TR199801395A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787464B1 (fr) * 1998-12-21 2003-01-10 Neurotech Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers
ATE275629T1 (de) 1999-04-02 2004-09-15 Hisamitsu Pharmaceutical Co Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
BR9917500A (pt) * 1999-09-23 2002-05-21 An Go Gen Inc Terapia gênica baseada em célula para o sistema pulmonar
US20030049635A1 (en) * 2000-11-08 2003-03-13 City Of Hope Measurement of mutation load using the p53 gene in human cells from paraffin embedded tissues
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7943378B2 (en) 2002-03-15 2011-05-17 Duke University Tissue engineering
EP1490477A4 (en) * 2002-04-02 2006-08-30 Univ Rice William M REDIFFERENCED CELLS USED TO REPAIR CARTILAGE DEFECTS
DK1458853T3 (da) * 2002-05-16 2010-04-06 Absorber Ab Fremgangsmåde til donorspecifik krydsmatchning
WO2005010157A2 (en) * 2003-07-15 2005-02-03 Cedars-Sinai Medical Center Use of pleiotrophin in the diagnosis, treatment and prevention of disease
KR100676922B1 (ko) * 2005-06-29 2007-02-05 정하철 혈 표시용 반지
JP2009511081A (ja) * 2005-10-18 2009-03-19 ナショナル ジューイッシュ メディカル アンド リサーチ センター 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法
RU2299073C1 (ru) * 2005-11-11 2007-05-20 ЗАО "РеМеТэкс" Биотрансплантат и способ лечения хронической сердечной недостаточности (варианты)
RU2308280C1 (ru) * 2006-03-21 2007-10-20 ГУ Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН) Способ клонирования in vitro регионарных клеток-предшественников сердца
RU2499599C2 (ru) * 2007-09-28 2013-11-27 Интрексон Корпорейшн Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
KR101803099B1 (ko) * 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
US9169462B2 (en) * 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
BRPI0921371A2 (pt) * 2008-11-25 2014-11-18 Otsuka Pharmaceutica Co Ltd Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.
WO2013186793A1 (en) 2012-06-11 2013-12-19 Council Of Scientific & Industrial Research Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
CA2879667C (en) 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
CN108138142A (zh) 2015-09-24 2018-06-08 塞莱克特生物疗法有限公司 繁殖用在移植中的间质干细胞（msc）的方法
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
EP3952909A4 (en) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
CA3137031A1 (en) 2019-05-14 2020-11-19 Yosef Refaeli Compositions and methods for treating t cell exhaustion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509467A (ja) * 1991-04-04 1994-10-27 アメリカ合衆国 内皮細胞の不死化
FR2681609B1 (fr) * 1991-09-24 1994-12-30 Centre Nat Rech Scient Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale.
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy

Also Published As

Publication number Publication date
HUP9801634A3 (en) 2003-07-28
HUP9801634A2 (hu) 1999-06-28
HU9801634D0 (en) 1998-09-28
AU757960B2 (en) 2003-03-13
BR9802542A (pt) 2000-01-11
KR19990014018A (ko) 1999-02-25
EP0893493A3 (de) 2002-12-04
AU7746698A (en) 1999-02-04
US20020098166A1 (en) 2002-07-25
EP0893493A2 (de) 1999-01-27
JPH1189587A (ja) 1999-04-06
CZ227198A3 (cs) 1999-02-17
PL327624A1 (en) 1999-02-01
RU2205029C2 (ru) 2003-05-27
CA2237698A1 (en) 1999-01-21
TR199801395A2 (xx) 1999-02-22
AR015926A1 (es) 2001-05-30

Similar Documents

Publication Publication Date Title
ID20600A (id) Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
FI973467A7 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
DE69826007D1 (de) Tetrafluorethylencopolymer und dessen verwendung
PT1151008E (pt) Peptidos artificiais com actividade de superficie e sua utilizacao na preparacao de tensioactivos artificiais
NO994438D0 (no) Terapeutisk aktive diarylpropylaminer samt fremstilling og anvendelse derav
ID16283A (id) Senyawa yang berguna dibidang farmasi
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
HUP0201997A3 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
AU1598599A (en) Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
DE69837507D1 (de) Humanes Hedgehog-Protein
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
ZA983740B (en) Novel amidine derivatives and their use in therapy
DK1328289T3 (da) Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36
NO20010044L (no) Anvendelse av texafyriner i makrofag-medierte sykdommer
NO990303D0 (no) Lipidbindende proteiner og deres terapeutiske og diagnostiske anvendelse
SI0966447T1 (en) Small molecules useful in the treatment of inflammatory disease
ID20900A (id) Tilam untuk ranjang perawatan dan metoda membuatnya
BA98291A (bs) Epoksi-azetidinoni priprava i upotreba
LT97027A (en) Use of the i-rna in the pharmaceuticals for increasing of the amount of protein encoded by said rna in patient cells
GB0029613D0 (en) Biological materials and the use thereof in the treatment of disease